FibroBiologics Enters into $6.15 Million At-The-Market Offering Agreement with H.C. Wainwright & Co.
On May 1, 2026, FibroBiologics, Inc. entered into an At The Market (ATM) Offering Agreement with H.C. Wainwright & Co., LLC. Under the terms of the agreement, the company may issue and sell shares of its common stock having an aggregate offering price of up to $6,150,000 from time to time. FibroBiologics intends to utilize the net proceeds from this offering for working capital and general corporate purposes. H.C. Wainwright & Co. will act as the sales agent and will receive a commission of 3.0% of the gross proceeds from any shares sold. The shares will be issued under the companyβs existing shelf registration statement on Form S-3, which was declared effective by the SEC on February 10, 2025. The company is not obligated to sell any shares under this agreement and may suspend or terminate the offering at any time. This ATM facility provides the company with a flexible mechanism to raise capital based on market conditions and internal requirements.